JP2013511990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511990A5 JP2013511990A5 JP2012541211A JP2012541211A JP2013511990A5 JP 2013511990 A5 JP2013511990 A5 JP 2013511990A5 JP 2012541211 A JP2012541211 A JP 2012541211A JP 2012541211 A JP2012541211 A JP 2012541211A JP 2013511990 A5 JP2013511990 A5 JP 2013511990A5
- Authority
- JP
- Japan
- Prior art keywords
- double
- nucleic acid
- stranded nucleic
- acid molecule
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 239000002773 nucleotide Substances 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 13
- 230000000692 anti-sense effect Effects 0.000 claims 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 8
- 108091081021 Sense strand Proteins 0.000 claims 8
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 5
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 5
- 229960005305 adenosine Drugs 0.000 claims 5
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 5
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 5
- 229940045145 uridine Drugs 0.000 claims 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 4
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 150000003838 adenosines Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 230000002194 synthesizing effect Effects 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 3
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 238000000137 annealing Methods 0.000 claims 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 229940029575 guanosine Drugs 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 244000089409 Erythrina poeppigiana Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 206010060872 Transplant failure Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- -1 deoxyribouridine Chemical compound 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 201000002761 non-arteritic anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 101150054147 sina gene Proteins 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26466809P | 2009-11-26 | 2009-11-26 | |
| US61/264,668 | 2009-11-26 | ||
| US29572110P | 2010-01-17 | 2010-01-17 | |
| US61/295,721 | 2010-01-17 | ||
| US37207210P | 2010-08-09 | 2010-08-09 | |
| US61/372,072 | 2010-08-09 | ||
| PCT/US2010/058123 WO2011066475A1 (en) | 2009-11-26 | 2010-11-25 | Sirna compounds comprising terminal substitutions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511990A JP2013511990A (ja) | 2013-04-11 |
| JP2013511990A5 true JP2013511990A5 (enExample) | 2014-01-09 |
Family
ID=43589717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541211A Pending JP2013511990A (ja) | 2009-11-26 | 2010-11-25 | 末端置換を含むｓｉＲＮＡ化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8796239B2 (enExample) |
| EP (1) | EP2504435B1 (enExample) |
| JP (1) | JP2013511990A (enExample) |
| KR (1) | KR20120102630A (enExample) |
| CN (1) | CN102597239A (enExample) |
| AU (1) | AU2010324658A1 (enExample) |
| CA (1) | CA2776568A1 (enExample) |
| DK (1) | DK2504435T3 (enExample) |
| ES (1) | ES2759003T3 (enExample) |
| IL (1) | IL218965A0 (enExample) |
| NZ (1) | NZ599237A (enExample) |
| TW (1) | TW201124160A (enExample) |
| WO (1) | WO2011066475A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG174367A1 (en) | 2009-03-23 | 2011-10-28 | Quark Pharmaceuticals Inc | Compounds compositions and methods of treating cancer and fibrotic diseases |
| AU2010324658A1 (en) * | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| ES2562499T3 (es) * | 2009-12-09 | 2016-03-04 | Nitto Denko Corporation | Modulación de la expresión de HSP47 |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| WO2012078536A2 (en) | 2010-12-06 | 2012-06-14 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| US9205100B2 (en) | 2011-03-03 | 2015-12-08 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
| JP6132775B2 (ja) | 2011-03-03 | 2017-05-24 | クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｔｏｌｌ様受容体経路のオリゴヌクレオチド修飾因子 |
| AU2012332517B9 (en) | 2011-11-03 | 2017-08-10 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
| EP2776565A1 (en) | 2011-11-08 | 2014-09-17 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| JP2015502365A (ja) * | 2011-12-12 | 2015-01-22 | オンコイミューニン，インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
| CN104080480A (zh) | 2012-01-01 | 2014-10-01 | 奇比艾企业有限公司 | 用于选择性递送治疗剂和诊断剂的endo180靶向微粒 |
| CA2880290C (en) | 2012-09-12 | 2020-10-27 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof |
| AU2013315524B2 (en) | 2012-09-12 | 2019-01-31 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
| US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
| EP3027222A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
| US20160208247A1 (en) | 2013-07-31 | 2016-07-21 | Qbi Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
| KR101696704B1 (ko) * | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
| KR101627404B1 (ko) * | 2014-04-08 | 2016-06-03 | 성균관대학교산학협력단 | Dab2 유전자가 넉 다운된 수지상 세포를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| DK3444349T3 (da) | 2014-05-29 | 2021-04-12 | Quark Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til forebyggelse af iskæmsik reperfusionslæsion i organer |
| US20160089391A1 (en) * | 2014-09-30 | 2016-03-31 | Temple University-Of The Commonwealth System Of Higher Education | Molecular Targets for Cardiovascular Disease |
| MA45469A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| KR20250004009A (ko) * | 2017-09-14 | 2025-01-07 | 애로우헤드 파마슈티컬스 인코포레이티드 | 안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법 |
| WO2019165267A1 (en) | 2018-02-22 | 2019-08-29 | The Regents Of The University Of California | Methods for treating brain injury |
| CN112331258B (zh) * | 2020-11-06 | 2024-02-23 | 大连大学 | 基于dna笼状结构的人工神经元计算模型构建方法 |
| KR102404883B1 (ko) * | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
| JP2024528697A (ja) | 2021-07-20 | 2024-07-30 | エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ | 微細藻類由来の細胞外小胞、その調製および使用 |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
| EP4608424A1 (en) | 2022-10-24 | 2025-09-03 | AGS Therapeutics SAS | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
| CN120574835B (zh) * | 2025-07-31 | 2025-10-03 | 羿美诚健(上海)生物医药有限公司 | 一种靶向rankl基因的小核酸及其在治疗骨科疾病中的应用 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| JPH08500481A (ja) | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ウイルスの複製を阻害するための方法および薬剤 |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| EP1602725A3 (en) | 1993-09-02 | 2006-03-29 | Sirna Therpeutics, Inc. | Abasic-nucleotide containing enzymatic nucleic acid |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000049035A1 (en) | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
| KR20070118315A (ko) | 1999-04-21 | 2007-12-14 | 와이어쓰 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물 |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9925459D0 (en) | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
| CA2390031A1 (en) | 1999-11-02 | 2001-05-25 | Chiron Corporation | Double-stranded rna receptor (dsrna-r) and methods relating thereto |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| AU2001263282A1 (en) | 2000-05-18 | 2001-11-26 | Commwell, Inc. | Method and apparatus for remote medical monitoring incorporating video processing and system of motor tasks |
| SI1407044T2 (en) | 2000-12-01 | 2018-03-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
| US20070032441A1 (en) | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| KR20100087400A (ko) | 2001-11-21 | 2010-08-04 | 가오루 사이고 | 유전자 발현 억제 방법 |
| WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| US20040254146A1 (en) | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| KR101201664B1 (ko) | 2002-08-05 | 2012-11-15 | 사일런스 테라퓨틱스 아게 | 신규한 형태의 간섭 ｒｎａ 분자 |
| AU2003291755A1 (en) * | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| US20050233342A1 (en) | 2003-03-07 | 2005-10-20 | Muthiah Manoharan | Methods of preventing off-target gene silencing |
| US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| ES2357116T5 (es) * | 2003-06-02 | 2021-09-03 | Univ Massachusetts | Métodos y composiciones para mejorar la eficacia y especificad de FNAi |
| PL1633767T3 (pl) | 2003-06-02 | 2019-07-31 | University Of Massachusetts | Sposoby i kompozycje do kontrolowania wydajności wyciszania rna |
| EP1636342A4 (en) | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | OLIGOMER COMPOUNDS FOR USE IN THE MODULATION OF GENES |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| EP1765416A4 (en) | 2004-06-03 | 2010-03-24 | Isis Pharmaceuticals Inc | DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION |
| US7582744B2 (en) | 2004-08-10 | 2009-09-01 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| WO2006023544A2 (en) | 2004-08-16 | 2006-03-02 | Quark Biotech, Inc. | Therapeutic uses of inhibitors of rtp801 |
| CA2580126C (en) | 2004-09-28 | 2014-08-26 | Quark Biotech, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| DOP2007000015A (es) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | Usos terapéuticos de inhibidores de rtp801 |
| WO2007087451A2 (en) | 2006-01-25 | 2007-08-02 | University Of Massachusetts | Compositions and methods for enhancing discriminatory rna interference |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| EP2026843A4 (en) | 2006-06-09 | 2011-06-22 | Quark Pharmaceuticals Inc | THERAPEUTIC USES OF RTP801L INHIBITORS |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| JP2010518880A (ja) | 2007-02-26 | 2010-06-03 | クアーク・ファーマスーティカルス、インコーポレイテッド | Ｒｔｐ８０１のインヒビター及びその疾患の治療における使用 |
| US20100292301A1 (en) | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| US7812002B2 (en) | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
| US20100273854A1 (en) | 2007-06-15 | 2010-10-28 | Hagar Kalinski | Compositions and methods for inhibiting nadph oxidase expression |
| PT2170403E (pt) | 2007-06-27 | 2014-07-17 | Quark Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes pró-apoptóticos |
| AU2008306455C1 (en) * | 2007-10-03 | 2014-04-17 | Quark Pharmaceuticals, Inc. | Novel siRNA structures |
| WO2009090639A2 (en) | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| KR101672563B1 (ko) | 2008-10-22 | 2016-11-03 | 쿠아크 파마수티칼스 인코퍼레이티드 | 안질환을 치료하는 방법 |
| AU2010324658A1 (en) * | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| ES2562499T3 (es) | 2009-12-09 | 2016-03-04 | Nitto Denko Corporation | Modulación de la expresión de HSP47 |
| WO2012078536A2 (en) | 2010-12-06 | 2012-06-14 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| US9205100B2 (en) * | 2011-03-03 | 2015-12-08 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
-
2010
- 2010-11-25 AU AU2010324658A patent/AU2010324658A1/en not_active Abandoned
- 2010-11-25 KR KR1020127012259A patent/KR20120102630A/ko not_active Withdrawn
- 2010-11-25 DK DK10785571T patent/DK2504435T3/da active
- 2010-11-25 WO PCT/US2010/058123 patent/WO2011066475A1/en not_active Ceased
- 2010-11-25 ES ES10785571T patent/ES2759003T3/es active Active
- 2010-11-25 CN CN201080049901XA patent/CN102597239A/zh active Pending
- 2010-11-25 TW TW099141067A patent/TW201124160A/zh unknown
- 2010-11-25 CA CA2776568A patent/CA2776568A1/en not_active Abandoned
- 2010-11-25 NZ NZ599237A patent/NZ599237A/en unknown
- 2010-11-25 JP JP2012541211A patent/JP2013511990A/ja active Pending
- 2010-11-25 US US13/511,111 patent/US8796239B2/en active Active
- 2010-11-25 EP EP10785571.0A patent/EP2504435B1/en not_active Not-in-force
-
2012
- 2012-04-01 IL IL218965A patent/IL218965A0/en unknown
-
2014
- 2014-08-04 US US14/451,233 patent/US9701960B2/en not_active Expired - Fee Related
-
2017
- 2017-07-06 US US15/642,581 patent/US10494631B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511990A5 (enExample) | ||
| RU2487716C2 (ru) | Новые структуры малых интерферирующих рнк (sirna) | |
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP2013535212A5 (enExample) | ||
| JP2020058368A5 (enExample) | ||
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2014509511A5 (enExample) | ||
| JP2018512110A5 (enExample) | ||
| JP2018512041A5 (enExample) | ||
| CN107532162A (zh) | 用于利用寡核苷酸编辑细胞中核酸的组合物和方法 | |
| CN103080314A (zh) | 显性突变基因表达抑制剂 | |
| JP2016513976A5 (enExample) | ||
| IL300119A (en) | Oligonucleotides to induce paternal UBE3A expression | |
| JP2017079776A5 (enExample) | ||
| JP2017079759A5 (enExample) | ||
| JP2013226147A5 (enExample) | ||
| JP2017536366A5 (enExample) | ||
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| JP2005517436A5 (enExample) | ||
| JP2013516190A5 (enExample) | ||
| JP2019534009A5 (enExample) | ||
| JP2014508161A5 (enExample) | ||
| JP2021505129A5 (enExample) | ||
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| JP2013537404A5 (enExample) |